Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Wrong potency or content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk.

992 FDA drug recalls with this cause, newest first.

These recalls cover sub-potent or super-potent products, or a failed content-uniformity test - meaning some pills in the same batch held noticeably different amounts of active ingredient than others. Either way it is a direct dosing risk: too little to work, or too much and harmful. Thyroid hormones and compounded injectables are the classic examples, because their dose window is narrow.

Class III · Low risk

Readyprep Chg

Superpotent Drug: Product is above specification for active ingredient, 2% Chlorhexidine Gluconate.

Terminated Wrong potency / content Medline Industries Inc D-0624-2021
Class II · Moderate risk

Lidocaine/Tetracaine

Superpotent Drug. Lidocaine higher concentration than listed

Terminated Wrong potency / content Stanley Specialty Pharmacy Compounding and Wellness Center D-0252-2021
Class II · Moderate risk

Sensorcaine-MPF

Subpotent Drug: Low out-of-specification assay results for the epinephrine component.

Terminated Wrong potency / content Fresenius Kabi USA, LLC NDC 63323-462-01 D-0172-2021